Formulation and evaluation of mouth dissolving film of polmacoxib

The current work concentrates on the analytical quantification and formulation development of Polmacoxib, a selective COX-2 inhibitor, by establishing a UV spectrophotometric calibration curve and characterizing mouth-dissolving films (MDFs). Using UV spectrophotometry, a standard calibration curve of Polmacoxib was created. It showed great linearity in the concentration range of 2–12 µg/mL, with a strong link between absorbance and concentration, which proved that it could be used for quantitative analysis. After the analytical validation, several mouth-dissolving film formulations (F1–F6) of Polmacoxib were made and tested for their mechanical strength, physicochemical characteristics, in vitro drug release, and stability. Formulation F5 stood out as the best of the bunch, with great film quality, high tensile strength (11.8 g/cm²), a quick disintegration time (10 ± 2 sec), and a very homogeneous drug concentration (98.4 ± 0.2%). In vitro dissolving experiments demonstrated that F5 attained a cumulative drug release of 98.4% at 12 minutes, surpassing a commercial formulation that released just 88.4% in the equivalent timeframe. FTIR spectroscopy showed that there was no substantial interaction between the medicine and the excipients, which meant that the formulation was compatible. Stability experiments conducted over 90 days showed that F5 kept its physical integrity, transparency, disintegration time, and drug release profile, proving that it is stable even when circumstances are sped up.